AIM ImmunoTech Inc.

Stocks

AIM

US00901B3033

Market Closed - NYSE Other stock markets 16:00:00 2026-06-26 EDT			5-day change	1st Jan Change
0.3121 ^USD	-12.18%		-17.85%	-72.35%

06-18	Aim Immunotech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 Duripanc Study in Metastatic Pancreatic Cancer	CI
06-18	AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient	MT

Transcript : AIM ImmunoTech Inc. - Special Call

Published on 06/04/2026 at 10:05 am EDT - Modified on 06/04/2026 at 11:35 am EDT

S&P Capital IQ

Presenter Speech
Jenene Thomas (Analysts)

Welcome back, and thank you for joining us today for another virtual investor What This Means segment. My name is Jenene Thomas. I am CEO of JTC IR, and I will

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about AIM ImmunoTech Inc.

06-18	Aim Immunotech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 Duripanc Study in Metastatic Pancreatic Cancer	CI
06-18	AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient	MT
06-09	AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement	MT
06-08	Aim Immunotech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen in Combination with Astrazeneca?S Imfinzi for the Treatment of Pancreatic Cancer	CI
06-08	AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell	MT
06-04	AIM ImmunoTech Inc. - Special Call
06-01	AIM ImmunoTech Inc. Completes Enrollment in Phase 2 DURIPANC Clinical Trial for Ampligen Combined with Imfinzi in Metastatic Pancreatic Cancer	CI
05-20	Top Premarket Decliners	MT
05-19	AIM ImmunoTech announces significant increase in stockholder equity and extension of promissory note maturity date to June 2027	RE
05-19	AIM ImmunoTech Inc. Amends Promissory Note Agreement With Streeterville Capital and Extends Maturity Date to June 30, 2027	CI
05-15	AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Aim ImmunoTech announces 50% objective response rate (ORR) in UPMC recurrent ovarian cancer Phase 2 clinical trial, suggesting breakthrough combination potential	RE
05-07	Aim Immunotech Inc Announces 50% Objective Response Rate in Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial	CI
04-16	AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer	MT
04-16	AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer	CI